[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"osteoarthritis-of-the-knee\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:osteoarthritis-of-the-knee":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,41,68,91,117,141],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100616176","efficacy-of-aerobic-exercise-versus-therapeutic-exercises-on-exercise-induced-hypoalgesia-in-knee-osteoarthritis-100616176",false,"NCT07302204","Efficacy of Aerobic Exercise Versus Therapeutic Exercises on Exercise-induced Hypoalgesia in Knee Osteoarthritis","Efficacy of Aerobic Exercise Versus Therapeutic Exercises on Exercise-induced Hypoalgesia in Knee Osteoarthritis. Randomized Clinical Trial","Inclusion Criteria:\n\n* Clinical diagnosis of symptomatic knee osteoarthritis for at least 3 months.\n* Report of knee pain for more than 3 months and average knee pain intensity ≥ 3 on the 0 to 10 Numeric Rating Scale.\n* Morning stiffness lasting less than 30 minutes.\n* Clinical signs compatible with knee osteoarthritis. crepitus, bony tenderness and absence of palpable warmth at the knee.\n* Altered exercise-induced hypoalgesia: absence of exercise-induced hypoalgesia and hyperalgesic response to exercise.\n\nExclusion Criteria:\n\n* Signs and symptoms indicating the hip as the main source of pain.\n* Osteoporosis\n* Fibromyalgia\n* History of tumors or cancer\n* Active inflammatory joint diseases, such as rheumatoid arthritis or gout.\n* Previous arthroplasty of any lower limb joint.\n* Neurological diseases, including Parkinson's disease, stroke, multiple sclerosis, muscular dystrophy, motor neuron disease or Alzheimer's disease.\n* Cardiovascular diseases for which exercise is formally contraindicated.\n* Infected wounds or osteomyelitis in the knee region.\n* Deep vein thrombosis or thrombophlebitis.\n* Sensory alterations in the lower limbs.\n* Cognitive or cardiopulmonary impairments that limit safe participation in the exercise program.\n* Use of walking aids.\n* Recent knee trauma.","ALL","40 Years","75 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","The study compares two exercise strategies in people with knee osteoarthritis. The first is aerobic exercise on a recumbent cycle ergometer, with effort controlled by the Borg scale. The second is a therapeutic exercise program with resistance, neuromuscular, mobility, and balance components. The primary objective is to determine which approach produces greater exercise induced hypoalgesia, measured by the increase in pressure pain threshold at the knee within the session across four anchor sessions during a ten week program. This is a randomized clinical trial with two parallel arms. Ninety participants, between forty five and seventy five years of age, will be allocated to one of the two groups. Allocation sequence concealment will be ensured using opaque envelopes. The outcome assessor will remain blinded to group allocation. The interventions will take place three times per week for ten weeks. Assessments will be performed at baseline and after ten weeks. Within session measurements will also be taken in weeks one, four, seven, and ten. The primary outcome is the intra session change in pressure pain threshold at the medial compartment of the knee. Secondary outcomes include exercise induced hypoalgesia in the quadriceps and trapezius, chronic adaptation of pressure pain threshold, conditioned pain modulation, pain intensity, pain self efficacy, knee related health status, functional performance, quadriceps strength, global perceived effect, and adherence. The planned sample size is forty five participants per group. The analysis will follow the intention to treat principle. The primary outcome will be compared using linear mixed models with group and time effects. Clinical outcomes at T1 will be adjusted for baseline values. Estimates, confidence intervals, and interpretation in light of minimally important differences will be reported.",[27],"Osteoarthritis of the Knee","RECRUITING","2026-06-22",{"date":31,"type":32},"2026-06-25","ACTUAL",{"date":34,"type":32},"2026-02-20",{"date":36,"type":21},"2029-12-20",{"name":38,"class":39},"University of Nove de Julho","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":67},"100618949","phase-1-study-to-assess-the-safety-and-pharmacokinetics-of-avd275-injection-in-patients-with-osteoarthritis-of-the-knee-100618949","NCT07338266","Study to Assess the Safety and Pharmacokinetics of AVD275 Injection in Patients With Osteoarthritis of the Knee","A Single Ascending Dose Study to Assess the Safety and Pharmacokinetics of Intra-articular AVD275 Injection in Patients With Osteoarthritis of the Knee","Inclusion Criteria:\n\n1. Written consent to participate in the study; Willingness and ability to comply with the study procedures, visit schedules and follow verbal and written instructions\n2. Male or female: 20 years to 75 years of age\n3. Symptoms associated with OA of the knee for ≥6 months prior to screening (patient reported is acceptable); Knee OA may be unilateral or bilateral\n4. Currently meets ACR Criteria (clinical and radiological) for OA as follows:\n\n   * Knee pain\n   * At least one of the following:\n\n     1. Age \\> 50 years\n     2. Stiffness \\\u003C 30 minutes\n     3. Crepitus\n   * Osteophytes\n5. Kellgren-Lawrence (K-L) Grade 1-4 in the index knee based on X-ray performed during screening (locally read) within 6 months from screening\n6. Body mass index (BMI) ≤ 40 kg\u002Fm2\n7. Ambulatory and in good general health\n\nExclusion Criteria:\n\n1. Any condition that could confound the patient's assessment of index knee pain in judgement of the investigator (for example, peri-articular pain of any cause or secondary arthritis that involves the index knee, joint dysplasia, aseptic osteonecrosis, acromegaly, Paget's disease, Ehlers-Danlos Syndrome, Gaucher's disease, Stickler's syndrome, hemophilia, hemochromatosis, or neuropathic arthropathy, radicular lower back pain and hip pain that is referred to the knee that could cause misclassification); Other chronic pain anywhere in the body that confounds assessment of knee or that requires the use of celecoxib\n2. Malalignment of greater than 10 degrees in the femorotibial axis of the index knee on standing; Unstable joint (such as tornanterior cruciate ligament) or traumatic knee injury to the index knee (such as meniscal root tear) within 12 months of screening\n3. Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, reactive arthritis, arthritis associated with inflammatory bowel disease, crystal disease of the index knee (e.g. gout or calcium pyrophosphate deposition disease), rapidly progressive osteoarthritis (defined as joint space narrowing \\> 1.2 mm\u002Fyear), sarcoidosis or amyloidosis\n4. Effusion at screening that likely requires joint aspiration for symptom relief from day 2 to day 83 during the study, as indicated by at least four joint drainages in the past year\n5. Intra-articular corticosteroids or intra-articular nonsteroidal antiinflammatory drugs (NSAIDs) (investigational or marketed) in the index knee within 2 months of screening; Intra-articular hyaluronic acid (investigational or marketed) in the index knee within 3 months of screening; Intra-articular Zilretta within 3 months of screening\n6. Intramuscular or oral corticosteroids within 1 month of screening\n7. Patients who received opioids (excluding tramadol and tapentadol) within 2 weeks of screening\n8. Any other investigational drug\u002Fbiologic use within 3 months of screening\n9. Prior diagnostic arthroscopy to the index knee within 3 months of screening; Prior arthroscopic or open surgery of the index knee (including microfracture and meniscectomy) within 6 months of screening；Prior regenerative joint procedures on the index knee, including, but not limited to, stem cells transplantation, autologous chondrocyte transplantation, or mosaicplasty within 12 months of screening; History of total or partial knee arthroplasty in the index knee\n10. Planned\u002Fanticipated surgery of the index knee, any other surgery, or hospitalization during the study period\n11. Known hypersensitivity to any form of NSAIDs (including celecoxib), sulfonamide-containing drugs, carboxymethyl cellulose, polysorbate 80 or lidocaine; History of severe allergic reactions\n12. Active or history of malignancy within the past 3 years, with the exception of resected basal cell carcinoma, squamous cell carcinoma of the knee, or effectively managed cervical carcinoma\n13. Known active or quiescent systemic fungal, bacterial (including tuberculosis), viral or parasitic infections (including HIV, hepatitis B or C viruses), or ocular herpes simplex; Any infection requiring intravenous antibiotics within 2 months of screening or oral antibiotics within 2 weeks of screening; History of infection in the index knee within 12 months of screening; History of osteomyelitis\n14. Any clinically significant laboratory parameters or ECG abnormality as judged by the investigator\n15. Uncontrolled diabetes as indicated by a hemoglobin A1c of \\>7.5% at screening\n16. History of atherosclerotic cardiovascular disease (ASCVD) defined as prior myocardial infarction, stroke (ischaemic or haemorrhagic), transient ischemic attack, coronary revascularization (e.g., PCI, CABG), peripheral artery disease, or heart failure (NYHA Class II or higher) in the past three years;\n\n    * OR a calculated 10-year ASCVD risk ≥10% based on age, sex, race, total\u002FHDL cholesterol, systolic blood pressure, diabetes, smoking status;\n    * OR current use of dual antiplatelet therapy, chronic anticoagulation (e.g., warfarin, direct oral anticoagulants), or high-dose aspirin (\\>300 mg\u002Fday)\n17. Abnormal liver function with AST or ALT \\> 2 upper limit of normal (ULN) at screening\n18. Abnormal kidney function with eGFR \\\u003C 45 mL\u002Fmin\u002F1.73m2 at screening\n19. Platelet count outside normal range at screening\n20. WBC count \\\u003C 3500 cells\u002Fmm3 or \\>20000 cells\u002Fmm3 at screening\n21. Active uncontrolled psychiatric disorder including psychosis (e.g. schizophrenia), bipolar disorder, uncontrolled anxiety disorder and major depressive disorder\n22. Positive drug screen (opiates, amphetamines, cocaine metabolites, benzodiazepines, cannabinoids); Active substance abuse (drugs or alcohol), history of chronic substance abuse within the past year, or prior chronic substance abuse judged by the investigator as likely to recur during the study\n23. Skin breakdown at the knee where the injection would take place; Any skin condition and\u002For tattoo that may interfere with the evaluation of safety at the injection site\n24. Women who are pregnant or nursing; Women of child-bearing potential (not surgically sterile or post-menopausal for at least 1 year as documented in medical history) not using a highly effective method of contraception (abstinence; oral, injected or implanted hormonal methods of contraception; intrauterine device or intrauterine system; condom or occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Fcream\u002Fsuppository; or male sterilization (vasectomy for at least 3 months))\n25. Any other clinically significant acute or chronic medical conditions (e.g. bleeding disorder) that, in the judgement of the investigator, would preclude the use of an intra-articular NSAID or that could compromise patient safety, limit the patient's ability to complete the study, and\u002For compromise the objectives of the study.","20 Years",{"count":50,"type":21},15,[52],"PHASE1","This study aims to understand the safety, drug concentration and distribution of an intra-articular injectable formulation of celecoxib, AVD275, in patients with knee osteoarthritis. One single injection at three different doses of the drug will be studied in a sequential order, and each participant will be monitored for 24 weeks over ten clinical visits.",[27],[56],"Osteoarthritis","2026-03-28",{"date":59,"type":32},"2026-03-31",{"date":61,"type":32},"2026-01-22",{"date":63,"type":21},"2026-12",{"name":65,"class":66},"Avidence Therapeutics","INDUSTRY",1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":5},"100558328","phase-3-a-phase-iii-study-of-cls2901c-in-patients-with-osteoarthritis-of-the-knee-100558328","NCT06549686","A Phase III Study of CLS2901C in Patients With Osteoarthritis of the Knee","A Phase III Study Evaluating the Efficacy and Safety of CLS2901C in Patients With Osteoarthritis of the Knee","Inclusion Criteria:\n\n1. Male or female aged 20 to 79 years at informed consent.\n2. Diagnosis of OAK classified as Kellgren-Lawrence (K-L) Grade 2 to 4 based on plain lower extremity X-ray.\n3. OAK eligible for proximal tibial osteotomy based on the following criteria: Range of motion (ROM): \\>=120 degree flexion, \\\u003C=5 degree extension\n4. Preoperative cartilage defect of the femoral condyle\u002Ftrochlear groove or medial tibial condyle with an area of \\>=4 cm2 per defect site.\n5. Total defect area of \\\u003C=21 cm2 in individuals with multiple cartilage defects.\n6. Body mass index (BMI) \\\u003C30.\n7. No coexisting ligament injury requiring surgery, and no meniscal injury requiring suturing or surgical repair other than partial resection, in the target knee.\n8. No history of ligament reconstruction, meniscal suturing, total meniscectomy or bone marrow stimulation, and no history of treatment with regenerative medicine products (including investigational products), cell processing products or gene therapy, in the target knee.\n9. No history of treatment with hyaluronic acid products and\u002For opioid for severe pain in the target knee within 1 month prior to informed consent.\n10. No history of treatment with corticosteroid products and\u002For immunosuppressive drug in the target knee within 3 months prior to informed consent.\n11. No history of platelet-rich plasma (PRP) therapy within 6 months prior to informed consent.\n12. Non-smoker; provided, however, that smokers will be eligible for study entry if they consent to abstain from smoking from 3 months prior to proximal tibial osteotomy or proximal tibial osteotomy+RMSC until postoperative bone healing.\n13. Written informed consent to participate in the study on a voluntary basis.\n\nExclusion Criteria:\n\n1. Requires surgical treatment of the non-target knee during the study period.\n2. Any coexisting illness that would interfere with surgery under general anesthesia or that would affect knee surgery.\n3. Systemic inflammatory disease such as rheumatoid arthritis.\n4. Systemic Active infectious disease such as bacterial, fungal or viral infection.\n\n6\\) Serious disease such as liver disorder, renal disorder, heart disease, lung disease, blood disease or metabolic disease that would make the patient unsuitable for study entry in the opinion of the investigator.\n\n7\\) Diagnosed or suspected malignant tumor or history of malignant tumor within the past 5 years.\n\n8\\) Uncontrolled psychiatric disorder. 9) Poorly-controlled diabetes (HbA1c: \\>7.0%). 10) septic arthritis of the target knee. 11) Women who are pregnant or breastfeeding, or women of childbearing potential. Women of childbearing potential must agree to use the following contraceptive methods (i.e., contraceptives and medical devices that are approved\u002Fcertified in Japan) or to abstain completely from sexual intercourse from the time of informed consent and for the study duration (excluding the follow-up period) in order to be eligible for study entry. (a) Primary contraceptive methods: Oral contraceptives, intrauterine devices (IUDs) including progesterone-releasing systems. (b) Adjunctive contraceptive methods: Condoms Use of a primary contraceptive method is mandatory, whereas use of the adjunctive contraceptive method must be in conjunction with a primary contraceptive method. Given that oral contraceptive doses can be missed and that their effects may be diminished when used concomitantly with other medications or dietary health supplements, subjects should consider changing their primary contraceptive method.\n\n12\\) Participated in another clinical study within the past 6 months, currently participating in another clinical study, or planning to participate in another clinical study while also participating in the present study.\n\n13\\) Known history of hypersensitivity to antibiotics (benzylpenicillin potassium, streptomycin sulfate, amphotericin B).\n\n14\\) Known history of hypersensitivity to bovine-derived materials. 15) Any other reason the investigator deems the subject unsuitable for study entry.","79 Years",{"count":77,"type":21},96,[79],"PHASE3","To evaluate the efficacy and safety of CLS2901C human allogenic chondrocyte sheets used in the osteotomy + RMSC group compared to in the osteotomy alone group of patients with osteoarthritis of the knee (OAK).",[27],"2025-11-21",{"date":84,"type":32},"2025-11-24",{"date":86,"type":32},"2023-10-20",{"date":88,"type":21},"2031-07-31",{"name":90,"class":66},"CellSeed Inc.",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":18,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":67},"100438695","phase-2-cannabinoid-interactions-with-central-and-peripheral-pain-mechanisms-in-osteoarthritis-of-the-knee-100438695","NCT04992624","Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee","Inclusion Criteria:\n\n* Ability to read and speak English to allow for written informed consent, phenotyping, and patient-reported outcomes measures\n* Willingness to participate in a drug intervention trial\n* Diagnosis of osteoarthritis (OA) of the knee by a medical provider (confirmed by checking medical records)\n* Chronic knee pain, defined as moderate to severe knee pain for ≥ 6-month duration\n* No use of cannabis or CBD in the past in the month prior to study enrollment as per self-report\n* Fibromyalgia (FM) Survey Criteria score available. The questionnaire will be assessed by the research team for scoring. We will recruit enough patients to satisfy the spectrum of FM scores in four quartiles based on our previously existing data. Once a quartile is filled (approximately 40 patients enrolled), then we will not include more people from that quartile.\n* Self-reported normal visual acuity or correctable (with corrective lenses- glasses or contacts) to at least 20\u002F40 for reading instructions in the MRI and visual sensitivity testing\n* No contraindications to magnetic resonance imaging (MRI) (for example (e.g.), metal implants)\n* Able to lie still on their back for 1-1.5 hours during MRI\n* Willingness to refrain from pain medications such as non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen for 12 hours prior to neuroimaging and Quantitative Sensory Testing (QST)\n* Willingness to refrain from alcohol and nicotine before QST and neuroimaging (alcohol and nicotine consumption is allowed after testing is completed)\n* Willingness to refrain from physical activity or exercise that would cause significant muscle and\u002For joint soreness for 48 hours prior to testing (routine exercise or activity that does not lead to soreness is acceptable)\n* Willingness to maintain a stable treatment regimen for chronic knee OA pain during the clinical trial (e.g., not initiating a new course of physical therapy)\n* No use of adjunctive pain medications or stable chronic daily use of adjunctive pain medications (excluding opioids)\n* Willingness to avoid grapefruit juice or food products for the duration of the study;\n* Females of reproductive potential must agree to use acceptable birth control from the screening visit and until the completion study drug administration. Sexually active male participants and\u002For their female partners must agree to use effective contraception during study drug treatment of the male participant. Male participants may also agree not to donate sperm during study drug treatment\n\nExclusion Criteria:\n\n* Individuals who are actively applying for or in litigation for compensation or disability and other aspects associated with potential secondary gain per self-report\n* Inability to provide written informed consent\n* Previous total knee arthroplasty\n* Planned total knee arthroplasty within the time frame of the study\n* Severe physical impairment (e.g., blindness, deafness, paraplegia)\n* Co-morbid medical conditions that may significantly impair physical functional status (e.g., history of non-skin malignancy, or autoimmune disorder)\n* Use of cannabis or CBD in the past month per self-report and\u002For drug screen\n* Current opioid use (excepting tramadol) per self-report and\u002For drug screen\n* Current valproate, clobazam, or warfarin use per self-report or medical records\n* Current use of moderate or strong inhibitors of cytochrome p450 (CYP) enzymes CYP3A4 and CYP2C19, strong inducers of CYP3A4 or CYP2C19, moderate or strong inhibitors\u002Finducers of CYP2C9, and narrow therapeutic index drugs (e.g., cyclosporine, amphotericin B). Participants will also not be allowed to start using these drugs during the study period if they wish to stay in the study\n* Self-reported allergies to sesame oil or cannabis\u002Fcannabinoids\n* Self-reported medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., schizophrenia, malignancy, psychosis, suicidal ideation, history of substance abuse; note that stable anxiety and depression are not exclusions)\n* Pregnant or nursing\n* Liver failure\n* Self-reported liver cirrhosis\n* Active diagnosis or current symptoms of hepatitis by self-report\n* Self-reported uncontrolled diabetes\n* Blood pressure at screening above 180 systolic and\u002For 120 diastolic\n* Resting heart rate at screening less than 50 beats per minute (bpm) or greater than 100 bpm;\n* Elevated liver enzymes and bilirubin (measured via blood test at screening):\n\n  * Serum total bilirubin ≥ 2.5 milligrams per deciliter (mg\u002FdL); or,\n  * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥ 3x upper limit normal (ULN); or,\n  * Alkaline phosphatase ≥ 2 times ULN\n* Severe cardiovascular disease (examples: history of myocardial infarction, unstable angina, severe coronary artery disease, congestive heart failure, or severe valvular abnormalities) that is self-reported by patient or by medical record\n* Severe claustrophobia precluding MRI\n* Unable to fit in or lie comfortably in MRI\n* Diagnosed peripheral neuropathy\n* Diagnosed or self-reported epilepsy or history of seizures\n* Current head injury or history of head injury (e.g., traumatic brain injury)\n* Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol","21 Years",{"count":99,"type":21},200,[101],"PHASE2","This clinical trial is being done to better understand how daily treatment with Tetrahydrocannabinol (THC), Cannabidiol (CBD), or the combination of CBD plus THC affects knee osteoarthritis pain and other related symptoms.\n\nConsented participants will have a screening period and visit (up to 30 days to treatment start). If participants pass the screening phase, they will be randomly assigned to take one of the investigational study drugs. For this study, participants will not know when or if they are taking CBD, THC, THC plus CBD, and when or if taking placebo.\n\nClinical pain will be assessed at multiple times throughout the study, and eligibility will be re-assessed at two weeks into the treatment period. It is possible that subjects will not be able to participate in the study after 14 days of of treatment. The treatment period will take approximately 16 weeks and then a follow-up period for approximately 2 weeks. In addition to treatment, participants will have clinical assessments, blood draws, questionnaires, daily pain diaries, sensory testing, as well as have functional connectivity magnetic resonance imaging (fcMRI).",[104,27],"Osteoarthritis, Knee",[106,107],"Cannabidiol","Tetrahydrocannabinol","2025-08-25",{"date":110,"type":32},"2025-09-02",{"date":112,"type":32},"2022-02-22",{"date":114,"type":21},"2026-10-31",{"name":116,"class":39},"Steven E Harte, PhD",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":67},"100514998","bone-marrow-aspirate-concentrate-bmac-vs-corticosteroid-injection-100514998","NCT05985785","Bone Marrow Aspirate Concentrate (BMAC) vs Corticosteroid Injection","Bone Marrow Aspirate Concentrate vs Corticosteroid Injection for Symptomatic Osteoarthritis (OA) of the Knee: A Randomized Controlled Trial","BMAC","Inclusion Criteria:\n\n* Patients between the ages of 18-70\n* Long standing knee pain from osteoarthritis (KL grade 2-3) despite conventional treatments such as activity modification, weight loss, physical therapy, analgesics, nonsteroidal anti-inflammatory drugs, or injection therapy for at least 6 weeks\n* 7-day average pain score of at least 4 on VAS scale\n\nExclusion Criteria:\n\n* Systemic diseases (Diabetes, malignancies, infections, etc.)\n* Post-traumatic arthritis\n* Patient had intra-articular injection on affected knee in last three months","18 Years","70 Years",{"count":128,"type":21},100,[24],"Prospective single-masked (study participant will be masked), randomized controlled trial to examine the influence of BMAC on patient-reported outcomes (PROs) in patients with primary knee osteoarthritis.",[27],"2025-08-12",{"date":134,"type":32},"2025-08-13",{"date":136,"type":32},"2022-07-19",{"date":138,"type":21},"2028-03-31",{"name":140,"class":39},"Rush University Medical Center",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":125,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":67},"100546015","robotic-assisted-versus-conventional-knee-endoprosthetic-techniques-100546015","NCT06389435","RObotic-assisted Versus Conventional Knee Endoprosthetic Techniques","ROCKETS: RObotic-assisted Versus Conventional Knee Endoprosthetic Techniques in a Randomized, Multicenter, Preference-tolerant Study","ROCKETS","Inclusion Criteria:\n\n* Adults aged 18 years and older.\n* Eligible for TKR according to local guidelines and routines.\n* Willingness to participate in the study.\n\nExclusion Criteria:\n\n* Patients with extreme malalignment necessitating special implants or techniques.\n* Patients unfit for surgery due to other medical reasons.\n* Patients who, for other reason such as alcohol or substance abuse, is deemed unsuitable to participate in the study.\n* Patients who, for other reasons can't fulfill the required patient recorded outcome measures",{"count":150,"type":21},250,[24],"Rationale for conducting the study:\n\nThe study aims to systematically evaluate the clinical and economic impacts of Robotic-Assisted Total Knee Replacement (RTKR) compared to conventional Total Knee Replacement (TKR). It focuses on the potential benefits of RTKR, including improved precision in surgery, potentially leading to better patient outcomes and reduced healthcare costs. Our primary endpoint is the Forgotten Joint Score (FJS), aimed at measuring patients awareness of their knee joint in everyday life, indicating the success of the knee replacement surgery in restoring natural joint function. Secondary endpoints include patient-reported outcome measures (PROMs), patient activity levels, the accuracy of implant positioning on x-ray, and the incidence of adverse events.\n\nStudy design:\n\nMulticentre,, preference-tolerant, randomized, controlled, superiority trial with two treatment arms that compares the outcomes of RTKR with traditional TKR techniques.\n\nStudy population:\n\nAdult patients aged 18 years and older who are eligible for TKR as per local guidelines and who have given informed consent to participate in the study.\n\nNumber of patients:\n\n400\n\nInclusion criteria:\n\nPatients must be adults aged 18 years and older, eligible for TKR according to local guidelines, and willing to participate in the study.\n\nExclusion criteria:\n\nPatients with extreme malalignment requiring special implants or techniques, patients unfit for surgery due to medical reasons, and those deemed unsuitable to participate in the study for other reasons.\n\nPrimary outcome variables:\n\nThe Forgotten Joint Score (FJS) at 2 years after surgery",[154,155,27],"Knee Arthroplasty, Total","Robotic-assisted",[157,158,159],"Knee arthroplasty","Robotic assisted","Osteoartritis","2024-04-26",{"date":162,"type":32},"2024-04-29",{"date":164,"type":32},"2024-03-04",{"date":166,"type":21},"2028-01",{"name":168,"class":39},"Danderyd Hospital"]